Vectus Biosystems Limited (AU:VBS) has released an update.
Vectus Biosystems Limited has partnered with C14 Consulting Group to spearhead the commercialization of its anti-fibrotic drug portfolio, including VB0004, which has shown promise in treating cardiovascular diseases and has successfully completed early human trials. C14, led by experienced CEO Martina Molsbergen, is recognized for its expertise in securing pharmaceutical commercial agreements, focusing on advancing Vectus’s outreach to potential partners. The collaboration is structured around a management fee and success-based incentives, ensuring aligned interests towards achieving commercial outcomes.
For further insights into AU:VBS stock, check out TipRanks’ Stock Analysis page.